2026-06-14T03:51:11Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/273462026-03-21T01:15:48Zcom_20.500.12105_19586com_20.500.12105_2202col_20.500.12105_19587

00925njm 22002777a 4500 dc Zatarain-Nicolás, Eduardo author Martín, Pilar author Márquez Rodas, Iván author Virizuela, Juan author Martín García, Ana author Mitroi, Cristina author Cosín Sales, Juan author Barrios, Vivencio author Sánchez-Cabo, Fátima author Ibañez, Borja author de Castro Carpeño, Javier author López Fernández, Teresa author 2023-11 Immune checkpoint inhibitors (ICI) have changed the prognosis of many tumors. However, concerning associated cardiotoxicity has been reported. Little is known about the real-life incidence-specific surveillance protocols or the translational correlation between the underlying mechanisms and the clinical presentation of ICI-induced cardiotoxicity. The lack of data from prospective studies led us to review the current knowledge and to present the creation of the Spanish Immunotherapy Registry of Cardiovascular Toxicity (SIR-CVT), a prospective registry of patients receiving ICI that aims to examine the role of hsa-miR-Chr8:96, (a specific serum biomarker of myocarditis) in the early diagnosis of ICI-induced myocarditis. An exhaustive prospective cardiac imaging study will be performed before and during the first 12 months of treatment. The correlation between clinical, imaging, and immunologic parameters may improve our understanding of ICI-induced cardiotoxicity and enable simpler surveillance protocols. We assess ICI-induced cardiovascular toxicity and describe the rationale of the SIR-CVT. Clin Transl Oncol. 2023 Nov;25(11):3073-3085 Clinical & Translational Oncology 37227656 https://hdl.handle.net/20.500.12105/27346 Cardio-oncology Cardiotoxicity Immune checkpoint inhibitors Myocarditis miRNA Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity.